Woodlands-based Opexa Therapeutics, Inc. Chief Scientific Officer, Don Healey, Ph.D., will serve as a guest speaker at this year’s Phacilitate Cell & Gene Therapy Forum, which will take place from January 27-29, 2014, at The Grand Hyatt in Washington, DC, according to a recent press release.
Dr. Healey’s invitation to the Phacilitate Cell & Gene Therapy Forum is a true honor for Opexa, as the organization’s academic and research pursuits are all closely aligned with Opexa’s approach to treating Multiple Sclerosis. Opexa’s lead experimental drug Tclena is a potential personalized therapy is designed to be customized for an MS patient’s disease profile, and is manufactured using the company’s ImmPath(R) technology, which uses a patient’s own T-cells to create personalized immunotherapy.
Considering that the Phacilitate Cell & Gene Therapy BioLeaders Forum will touch on topics relating to stem sells, cell and gene therapy, and immunotherapy, having one of Opexa’s key executive thought leaders at the forum is a rousing endorsement of the company’s innovative approach to offering effect treatment options for Multiple Sclerosis, and particularly secondary progressive MS, which the company is currently testing Tcelna in a series of clinical trials.
At the forum, Dr. Healey “will discuss the design and value of potency assays to render them more relevant to cell and gene therapy and more appropriate to clinical practice/benefit, during the focus session, “Process Standardization and Comparability – Do We Need a Rethink?” Dr. Healey’s presentation, entitled, “Individual Lots of Autologous Product, All the Same but Different: The Potency Conundrum” will take place on Monday, January 27th at 12pm EST.” The forum will include researchers and business leaders who will seek to further advance the maturation of regulatory, manufacturing, R&D and commercial strategies.